Could α MSH-MIFT Axis and IDH2 Be Considered Promising Predictors of Non-segmental Vitiligo Response to NB-UVB Phototherapy?

Overview

Journal J Clin Aesthet Dermatol

Date 2023 Feb 6

PMID 36743971

Authors

Khaled Mohey El-Din Monib

Neveen Emad Sorour

Naglaa Fathy Alhusseini

Asmaa Gaber Abdou

Amal Yousif

Rehab Mohammed Salem

Affiliations

Soon will be listed here.

Abstract

Background: The search for objective factors that help in predicting the response of vitiligo treatment is very important.

Objective: We sought to evaluate the effect of NB-UVB phototherapy on both the alpha melanocyte stimulating hormone-microphthalmia-associated transcription factor (α-MSH-MIFT) axis, and isocitrate dehydrogenase 2 (IDH2) in non-segmental vitiligo (NSV).

Methods: This prospective clinical trial included 50 NSV patients and 50 healthy control subjects. α-MSH tissue levels as well as MITF and IDH2 immunostaining were assessed in normal and vitiliginous skin biopsies before treatment and then in the repigmented areas following 24 NB-UVB phototherapy treatment sessions using ELISA technique and immunohistochemical study, respectively.

Results: There was a significant negative correlation between baseline VASI scores and the tissue levels of α-MSH (=0.006) and the expression of both MITF (<0.00001) and IDH-2 (= 0.001). The mean α-MSH tissue levels increased significantly after treatment (<0.001). Tissue expression of both MTIF and IDH-2 was significantly upregulated following treatment (-value <0.001). The percentage of improvement showed a significant positive correlation with the studied markers (<0.00001).

Conclusion: α-MSH- MIFT axis and the antioxidant protein IDH2 are promising objective markers of non-segmental vitiligo severity, and are suggested as predictors of vitiligo response to treatment.

References

Luisa Kadekaro A, Chen J, Yang J, Chen S, Jameson J, Swope V . Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol Cancer Res. 2012; 10(6):778-86. DOI: 10.1158/1541-7786.MCR-11-0436. View

Salem R, Abdelrahman A, Abd El-Kareem H, Seif M . DEFB1 gene polymorphisms modify vitiligo extent and response to NB-UVB phototherapy. Dermatol Ther. 2021; 34(3):e14921. DOI: 10.1111/dth.14921. View

Kawakami A, Fisher D . The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest. 2017; 97(6):649-656. DOI: 10.1038/labinvest.2017.9. View

Park J, Ku H, Lee J, Park J . Deficiency Exacerbates Acrolein-Induced Lung Injury through Mitochondrial Redox Environment Deterioration. Oxid Med Cell Longev. 2018; 2017:1595103. PMC: 5804324. DOI: 10.1155/2017/1595103. View

Spencer J, Schallreuter K . Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/melanocortin-4 receptor signaling. Endocrinology. 2008; 150(3):1250-8. DOI: 10.1210/en.2008-1212. View

Morales-Sanchez M, Vargas-Salinas M, Peralta-Pedrero M, Olguin-Garcia M, Jurado-Santa Cruz F . Impact of Vitiligo on Quality of Life. Actas Dermosifiliogr. 2017; 108(7):637-642. DOI: 10.1016/j.ad.2017.03.007. View

Guntas G, Engin B, Ekmekci O, Kutlubay Z, Ekmekci H, Songur A . Evaluation of advanced oxidation protein products, prooxidant-antioxidant balance, and total antioxidant capacity in untreated vitiligo patients. Ann Dermatol. 2015; 27(2):178-83. PMC: 4377407. DOI: 10.5021/ad.2015.27.2.178. View

Yardman-Frank J, Fisher D . Skin pigmentation and its control: From ultraviolet radiation to stem cells. Exp Dermatol. 2020; 30(4):560-571. PMC: 8218595. DOI: 10.1111/exd.14260. View

Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H . Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004; 140(6):677-83. DOI: 10.1001/archderm.140.6.677. View

10.

Chen J, Li S, Li C . Mechanisms of melanocyte death in vitiligo. Med Res Rev. 2020; 41(2):1138-1166. PMC: 7983894. DOI: 10.1002/med.21754. View

11.

Karsli N, Akcali C, Ozgoztasi O, Kirtak N, Inaloz S . Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res. 2014; 42(3):799-805. DOI: 10.1177/0300060513516294. View

12.

Gauthier Y, Almasi-Nasrabadi M, Cario-Andre M, Pain C, Rakhshan A, Ghalamkarpour F . Tacrolimus (FK506) ointment combined with Nb-UVB could activate both hair follicle (HF) and dermal melanocyte precursors in vitiligo: the first histopathological and clinical study. Arch Dermatol Res. 2020; 313(5):383-388. DOI: 10.1007/s00403-020-02068-z. View

13.

Njoo M, Das P, Bos J, Westerhof W . Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999; 135(4):407-13. DOI: 10.1001/archderm.135.4.407. View

14.

Garcia-Borron J, Abdel-Malek Z, Jimenez-Cervantes C . MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res. 2014; 27(5):699-720. PMC: 4150834. DOI: 10.1111/pcmr.12257. View

15.

Khanna U, Khandpur S . What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo?. Indian Dermatol Online J. 2019; 10(3):234-243. PMC: 6536079. DOI: 10.4103/idoj.IDOJ_310_18. View

16.

Monib K, Sabry H, Hussein M, El-Fallah A, Salem R . Factors affecting vitiligo response to treatment: do MiRNA 196a2C/T gene polymorphism and serum tyrosinase levels have any role?. J Dermatolog Treat. 2020; 33(3):1351-1355. DOI: 10.1080/09546634.2020.1810202. View

17.

Fang D, Setaluri V . Role of microphthalmia transcription factor in regulation of melanocyte differentiation marker TRP-1. Biochem Biophys Res Commun. 1999; 256(3):657-63. DOI: 10.1006/bbrc.1999.0400. View